Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical compound preparation for treating hyperparathyroidism

A technology of compound preparations and parathyroid glands, which is applied in the direction of drug combinations, pharmaceutical formulas, and medical preparations containing active ingredients, etc., can solve the problems of patients' depression and serious complications, and achieve fewer sequelae, convenient administration, and safe use Effect

Inactive Publication Date: 2018-01-16
CHENGDU LINGXI SHANGPIN TECH CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The existing treatment method adopts surgical resection of parathyroid adenoma, but its complications are serious, and it is easy to cause depression in patients, so there is no drug compound preparation that is better for the treatment of hyperparathyroidism

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical compound preparation for treating hyperparathyroidism
  • Pharmaceutical compound preparation for treating hyperparathyroidism

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] The compound oral preparation of this embodiment is prepared by a method known in the pharmaceutical industry, and the specific dosage of each component is shown in Table 1:

[0018] Table 1 The specific dosage of each component

[0019]

[0020]

[0021] The treatment effect of using two oral medicines of cimetidine and shimmermycin mixed at the same time shows that the effect of using cimetidine and shimmermycin is better than that of a single medicine, thus providing a reasonable combination for the development of two kinds of medicines. The compound preparation used has laid the foundation.

Embodiment 2

[0023] Validation of therapeutic effect in rat model:

[0024] Objective: To observe the effect of compound preparations of different ratios of cimetidine combined with shimmermycin on DOCA (deoxycorticosterone acetate) rats with hyperparathyroidism, so as to explore the therapeutic effects of different doses in the compound. effect.

[0025] Methods: 1200 SD rats, ♂, body weight 180-190g. After resecting the right kidney under aseptic conditions, DOCA 5mg / cattle was administered twice a week, sc, and fed with 1% sodium chloride solution; they were randomly divided into 12 groups, 8 in each group, and the specific grouping and treatment were shown in the table two.

[0026] Table 2 Animal grouping and drug formulation, administration method

[0027] model group

normal saline

Cimetidine group

Cimetidine 400 mg

Mitsumycin high group

Mithromycin 40 mg

compound group

Cimetidine 20 mg, Mithromycin 2 mg

Compound two group

C...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical compound preparation for treating hyperparathyroidism. The compound preparation comprises the following components in parts by weight: 10 to 300 parts of cimetidine, 10 to 120 parts of mithramycin, and 10 to 1600 parts of drug carrier. Cimetidine and mithramycin are taken as the pharmaceutical components and mixed with the drug carrier to prepare the compound preparation. The compound preparation is convenient to take, is very safe, has a prominent effect, can greatly reduce complications, generates few sequelae, barely causes adverse reactions, and promotes the healing.

Description

technical field [0001] The invention relates to the field of drug compound preparations, in particular to a drug compound preparation for treating hyperparathyroidism. Background technique [0002] Hyperparathyroidism can be divided into three types: primary, secondary, and tertiary. Primary hyperparathyroidism is due to the excessive secretion of parathyroid hormone (PTH) caused by the lesions (tumor or hyperplasia) of the parathyroid gland itself, which leads to hypercalcemia and hypophosphatemia through the effect on bones and kidneys. Secondary hyperparathyroidism is due to hypocalcemia caused by various reasons other than the thyroid gland, secondary to parathyroid hyperplasia and excessive secretion of PTH. Tertiary hyperparathyroidism On the basis of secondary hyperparathyroidism, due to the persistent stimulation of the parathyroid glands, excessive parathyroid hyperplasia transforms into an adenoma that can secrete PTH autonomously. This situation is called tertiar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61P5/16A61K31/4164
Inventor 姜迪蛟
Owner CHENGDU LINGXI SHANGPIN TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products